By Dean Seal Shares of Adial Pharmaceuticals advanced after the company regained compliance with Nasdaq listing requirements. The stock was up 6.6% at $2.27.
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL – Free Report) – Stock analysts at Brookline Capital Management decreased their FY2023 earnings per share (EPS) estimates for Adial Pharmaceuticals in a research note issued on Tuesday, November 14th. Brookline Capital Management analyst K. Dolliver now expects that the company will earn ($5.46) per share for the year, down from […]
By Chris Wack Adial Pharmaceuticals shares were down 24% at $2.13 after the company entered into definitive agreements for the purchase and sale of 1.4.
By Chris Wack Adial Pharmaceuticals shares were up 5%, to $2.90, after the biopharmaceutical company was awarded a notice of allowance for a patent. The.